The Institute of Cancer Research (ICR) has treated the first patient in a new clinical trial designed to overcome resistance to cancer immunotherapy in lung cancer and melanoma.

The announcement marks the transition of the programme from laboratory concept to clinical testing. The trial will enrol patients with the two tumour types in which checkpoint inhibitors are most widely used, and where resistance — intrinsic or acquired — remains the central barrier to durable responses.

For the dermatology and cutaneous-oncology community, the melanoma arm carries the most immediate weight. Immune checkpoint blockade has transformed outcomes in advanced melanoma, yet a substantial share of patients either never respond or relapse after an initial response. A trial that interrogates the mechanisms behind that failure speaks directly to a clinical problem oncologists and dermatologists face in managing stage III and IV disease.

What do we know about the trial?

The ICR disclosed that the study has passed its first clinical milestone: the first participant has received treatment. The institute positioned the trial explicitly around immunotherapy resistance in lung cancer and melanoma, indicating that patient selection focuses on tumours that have failed, or are expected to fail, standard checkpoint-inhibitor strategies.

No enrolment target, primary endpoint, or phase designation accompanied the announcement. Those specifics will determine how quickly results translate into practice for resistant melanoma, and Derm Field will track the trial registry entry and protocol details as they are published.

Why does resistance matter in melanoma?

Checkpoint inhibitors targeting PD-1 and CTLA-4 pathways are the backbone of modern advanced-melanoma therapy. When they work, responses can be deep and long-lasting. When they do not, options narrow considerably, and the biology of why a tumour escapes immune attack remains incompletely mapped.

A dedicated resistance-focused trial signals that investigators are now testing that biology prospectively in patients rather than retrospectively in tissue banks. That shift — from correlation to intervention — is what turns mechanistic hypotheses into usable clinical knowledge.

Lung cancer, the second tumour type in the study, shares the same therapeutic backbone and the same resistance problem, which gives the trial a broader evidence base and, potentially, a faster route to signal detection across two indications at once.

What happens next?

With the first patient treated, the trial now moves into dose and safety evaluation and accrual. Dermatologists managing melanoma patients who progress on checkpoint inhibitors should watch for the protocol's eligibility criteria, since resistance-focused studies often define entry by prior therapy and progression pattern — details that will shape referral decisions.

The ICR has not announced a readout timeline. Upcoming disclosures on dosing, safety data, and biomarker selection will determine whether this approach can meaningfully extend immunotherapy benefit to patients whose cancers have learned to evade it.